Literature DB >> 3533081

Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment.

C R Fairchild, J Maybaum, K A Kennedy.   

Abstract

The delayed cytotoxicity of 6-thioguanine (TG) may relate to the arrest of cells in G2 upon completion of one cell cycle after drug exposure. In Chinese hamster ovary (CHO) cells, both the unilateral chromatid damage in G2 chromosomes, determined by induction of premature condensed chromosome condensation [Maybaum and Mandel, Cancer Res. 43, 3852 (1983)], and incorporation of TG into DNA resulting in DNA strand breakage [Christie et al., Cancer Res. 44, 3665 (1984)] were correlated with cytotoxicity. We have studied the correlation between strand breakage and unilateral chromatid damage in L1210 cells. DNA breaks were detected only when cells were treated with TG (0.25 microM) for one cell cycle time (12 hr) followed by 12 hr in drug-free medium containing [3H]thymidine (TdR) to label the DNA. After simultaneous incubation of cells with drug and label during the first or second 12-hr period, strand breaks were not found. Strand breaks increased with dose, which correlated with greater cytotoxicity (0.01 to 0.25 microM). Treatment of cells with 0.25 microM TG for 12 hr, and transfer to drug-free medium for 12 hr prior to making prematurely condensed chromosomes (PCC), resulted in unilateral chromatid damage. Prominent curving of G2 chromosomes with gapping and diffuse staining of one of the sister chromatids occurred. The 4-fold increase in the percentage of cells in G2 compared with control cells suggested G2 arrest. When cells were treated with TG for 12 hr and PCC made immediately, neither the arrest of cells in G2 nor unilateral chromatid damage was observed. These data suggest that strand breaks and unilateral chromatid damage occur in the second cell cycle after TG exposure and that this damage may be important in TG-delayed cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533081     DOI: 10.1016/0006-2952(86)90623-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  20 in total

1.  Structural effect of the anticancer agent 6-thioguanine on duplex DNA.

Authors:  Jen Bohon; Carlos R de los Santos
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

Review 2.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.

Authors:  C Cuffari; S Hunt; T Bayless
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

4.  A Physician's Guide to Azathioprine Metabolite Testing.

Authors:  Carmen Cuffari
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

Review 5.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

6.  Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells.

Authors:  H T Hassan; J K Rees
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

7.  Modulation of the cytotoxic mechanism of 6-thioguanine by 4-amino-5-imidazolecarboxamide.

Authors:  J Maybaum; C W Morgans; P Ting; C E Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.

Authors:  Ahmed F Hawwa; Paul S Collier; Jeff S Millership; Anthony McCarthy; Sid Dempsey; Carole Cairns; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

9.  The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Christabelle M Chen; Harpal K Marway; Sean McKeag; Charles V J Mifsud; Andrew M Pilling; Matthew J Whayman; John A Turton
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

10.  Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy.

Authors:  C Cuffari; D Y Li; J Mahoney; Y Barnes; T M Bayless
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.